Search results for "Heart"
showing 10 items of 3201 documents
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
2015
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…
Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients
2018
Introduction: Cardiovascular (CV) comorbidities are common in COPD, and associated with poor prognosis. LABAs and LAMAs are established COPD treatments whose pharmacology would suggest the potential to increase heart rate (HR) and impact blood pressure (BP). However, previous studies indicate that HR and BP are not negatively influenced by tiotropium (Tio) or olodaterol (Olo) monotherapy. Aims: To determine the effect of dual bronchodilation with Tio/Olo (T/O) on HR and BP. Methods: The 52-week, Phase III TONADO® studies (NCT01431274/NCT01431287) evaluated T/O 5/5 µg, Tio 5 µg or Olo 5 µg, via the Respimat® inhaler, in GOLD 2–4 COPD patients. In this post hoc analysis, long-term changes fro…
Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients
2021
Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease with poor outcomes, including a high mortality. GULP is a multicenter Italian study that described clinical characteristics, exacerbation rates and survival of a cohort of COPD patients, as part of AstraZeneca’s AvoidEX program. Aims and objectives: To evaluate whether the clinical profile of subjects enrolled in the GULP study predicts mortality on a period of 3 years. Methods: Post-hoc analysis of an observational, multicenter, retrospective study. Patients were stratified according to survival status: alive (A) and dead (D). Clinical characteristics, comorbidities and exacerbation rates were reported in the…
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
2021
Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…
Determinants of procalcitonin concentration in acute heart failure.
2014
Age, years 73.1 ± 10.4 Male, n (%) 133 (51.0) Hypertension, n (%) 212 (81.2) Diabetes mellitus, n (%) 126 (49.4) Previous smoker, n (%) 104 (28.2) Ischemic etiology, n (%) 92 (35.3) Peripheral oedema, n (%) 187 (71.7) Previous admission for AHF, n (%) 95 (36.4) Prior use of beta-blockers, n (%) 111 (42.5) Prior use of loop diuretics, n (%) 175 (67.0) Prior use of ACEI/ARB, n (%) 134 (51.3) Heart rate, beats/min 97 ± 28 SBP, mm Hg 148 ± 34 DBP, mm Hg 81 ± 19 Atrial fibrillation, n (%) 119 (45.6) Hemoglobin, g/dl 12.1 ± 2.0 Serum creatinine, mg/dl 1.23 ± 0.57 Urea, mg/dl 60.5 ± 30.1 Sodium, mEq/l 137.8 ± 4.7 NT-proBNP, pg/ml 4813 (6011) Leukocyte count, 10 cells/l 9286 ± 3468 Relative lymphoc…
Procalcitonin and long-term prognosis after an admission for acute heart failure
2014
Abstract Background Traditionally, procalcitonin (PCT) is considered a diagnostic marker of bacterial infections. However, slightly elevated levels of PCT have also been found in patients with heart failure. In this context, it has been suggested that PCT may serve as a proxy for underrecognized infection, endotoxemia, or heightened proinflammatory activity. Nevertheless, the clinical utility of PCT in this setting is scarce. We aimed to evaluate the association between PCT and the risk of long-term outcomes. Methods and results We measured at admission PCT of 261 consecutive patients admitted for acute heart failure (AHF) after excluding active infection. Cox and negative binomial regressi…
Utility of Procalcitonin for Diagnosis of Superimposed Infections in Patients With Acute Heart Failure.
2016
Respiratory infections are well-known precipitant factors for heart failure decompensations. Nevertheless, the diagnosis of life-threatening infections, such as pneumonia, is challenging. Pneumonia and acute heart failure often display overlapping clinical findings and, in other cases, more accurate infection-related findings are missing. In recent years, procalcitonin has emerged as a promising tool for early and accurate diagnosis of pneumonia and, interestingly, for guiding antibiotic therapy in patients with acute heart failure. We discuss two cases of acute heart failure with high procalcitonin on admission and different clinical outcomes. In this setting, procalcitonin may be a useful…
Dibutyryl cyclic AMP and adrenaline increase contractile force and 45Ca uptake in mammalian cardiac muscle
1973
The effects of dibutyryl cyclic AMP (DB-AMP; 10−3M) and adrenaline (2.2×10−6 M) on contractile force, 45Ca uptake, and total myocardial Ca concentration were investigated in electrically driven left auricles isolated from rat hearts. The experiments were performed at an extracellular Ca concentration of 0.45 mM and at low frequency of stimulation (15 beats/min). 45Ca exposure was 5 min. Under the conditions used, both drugs increased contractile force and enhanced 45Ca uptake (expressed as relative specific activity) by about 30% (DB-AMP) and 40% (adrenaline), respectively. Thus, the results provide evidence that the effects of adrenaline on 45Ca uptake in mammalian cardiac muscle can be mi…
CaMKII inhibition reduces electrical activation heterogeneities caused by mechanical stretch in the myocardium
2020
Abstract Introduction Ca2+/calmodulin-dependant protein kinase II (CaMKII) activity in cardiomyocytes plays a crucial role in their contractility. Increased CaMKII signalling has been associated with mechanical stretch, often caused in the border zone of myocardial infarction. CaMKII upregulation causes a mishandling of intracellular calcium, a precursor of multiple pro-arrhythmic mechanisms, such as early afterdepolarisations. Purpose In this study, we aim to quantify the effects of KN-93 -a CaMKII inhibitor- on wave dynamics, in order to investigate its effectiveness as an anti-arrhythmic agent. Methods An isolated Langendorff model was constructed based on rabbit hearts (n=18) and poster…
Managed ventricular pacing vs. conventional dual-chamber pacing for elective replacements: the PreFER MVP study: clinical background, rationale, and …
2008
Udgivelsesdato: 2008-Mar AIMS: Several clinical studies have shown that, in patients with intact atrioventricular (AV) conduction, unnecessary chronic right ventricular (RV) pacing can be detrimental. The managed ventricular pacing (MVP) algorithm is designed to give preference to spontaneous AV conduction, thus minimizing RV pacing. The clinical outcomes of MVP are being studied in several ongoing trials in patients undergoing a first device implantation, but it is unknown to what extent MVP is beneficial in patients with a history of ventricular pacing. The purpose of the Prefer for Elective Replacement MVP (PreFER MVP) study is to assess the superiority of the MVP algorithm to convention…